NCT01737008View on ClinicalTrials.gov

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

May 31, 2015

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

dacomitinib

Tablets are administered orally or through a G-Tube, and can be taken with or without food.

RADIATION

Radiotherapy

Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.

DRUG

Cisplatin

If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01737008 - Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter